Compare Eli Lilly And Co (LLY) vs Transocean Ltd (RIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Transocean Ltd — how do they compare? Eli Lilly And Co trades at $1,177.57 (market cap $1.04T), while Transocean Ltd trades at $5.53 (market cap $6.19B). The key difference: Eli Lilly And Co is far larger — about 168× Transocean Ltd's market cap, and Eli Lilly And Co pays a 0.59% dividend while Transocean Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Transocean Ltd for 18 Days on average.
| LLY | RIG | |
|---|---|---|
Market Cap | $1.04T | $6.19B |
Volume | 3,064,878 | 30,564,415 |
Sector | Health | Energy |
52-Week High | $1.28K | $7.58 |
52-Week Low | $799.57 | $3.08 |
Typical Hold Time | 93 Days | 18 Days |
Enterprise Value | $1.09T | $10.80B |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
Transocean (RIG) trades at $5.55, up 2.97% on the day, with a bullish technical signal driven by oscillators. The company reported a Q2 2026 EPS beat but remains unprofitable with a net income margin of -40.24%. Recent news highlights progress on the $5.8 billion Valaris acquisition and new contract awards, supporting cash flow growth. The stock shows mixed analyst sentiment with a 39.06% buy rating.
The outlook is speculative, hinging on successful deleveraging and offshore cycle strength. Investment opportunity lies in cash flow improvement and backlog execution, but risks include high debt, execution challenges from the Valaris deal, and persistent negative profitability. The stock presents a high-risk, event-driven play for investors betting on an offshore drilling recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Transocean Ltd
Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.
Read more on RIG →
